Here are the 10-K annual reports from Mangoceuticals, Inc. (MGRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MGRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGRX filings page.
Mangoceuticals, Inc. is a Texas-based telehealth company focused on men’s wellness, selling compounded products for erectile dysfunction, hair loss, hormone balance and weight management, plus an FDA-approved oral testosterone therapy under the MangoRx brand.
In October 2024 the company completed a 1-for-15 reverse stock split, cutting outstanding common shares from roughly 35.5 million to about 2.4 million, with options and warrants adjusted proportionately. As of March 31, 2026, it had 16,967,420 common shares outstanding and a non-affiliate market value of about $14.7 million as of June 30, 2025.
Mangoceuticals relies on related-party pharmacy Epiq Scripts and contracted telehealth providers to prescribe and fulfill its products across nearly all U.S. states. It is expanding via master distribution agreements, a $20 million patent acquisition for respiratory illness prevention technology, and a new subsidiary, Mango & Peaches, which now holds most operating assets and is majority controlled by the CEO through high-vote preferred stock.
The company also outlines a planned digital asset treasury strategy, aiming to deploy up to $100 million into Solana-based holdings through a managed structure targeting staking yields of roughly 7–8%, though no funds have yet been committed and significant additional capital would be required.